Ensign Peak Advisors
ORKA icon

Ensign Peak Advisors’s Oruka Therapeutics ORKA Stock Holding History

Ensign Peak Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.89M Sell
58,707
-8,961
-13% -$844K 0.01% 578
2026
Q2 		$6.44M Sell
67,668
-11,712
-15% -$780K 0.01% 520
2026
Q1 		$3.89M Buy
+79,380
New +$2.76M 0.01% 575
2025
Q1 		– Sell
-25,000
Closed -$485K – 1734
2024
Q4 		$485K Hold
25,000
– – ﹤0.01% 1605
2024
Q3 		$613K Buy
+25,000
New +$870K ﹤0.01% 1551

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Remedium Capital Partners
Remedium Capital Partners Fort Lauderdale, Florida $274M AUM 288.41% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Ensign Peak Advisors's ORKA Position: Q3 2026 in Review

Ensign Peak Advisors reduced its Oruka Therapeutics (ORKA) stake by 13% in Q3 2026, selling an estimated $844K and leaving 58,707 shares worth $4.89M. The position accounts for 0.01% of the portfolio, ranked #578.

Ensign Peak Advisors first reported a position in ORKA in Q3 2024 and has held it in 5 quarters since. The position peaked at $6.44M in Q2 2026. 175 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Ensign Peak Advisors held 58,707 shares of Oruka Therapeutics worth $4.89M as of Q3 2026.
  • Ensign Peak Advisors sold 8,961 Oruka Therapeutics shares in Q3 2026, an estimated $844K.
  • Oruka Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #578 holding.
  • Ensign Peak Advisors first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Ensign Peak Advisors's Oruka Therapeutics position peaked at $6.44M in Q2 2026.
  • 175 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.